The Global Polio Eradication Initiative (GPEI) is
at a historical moment. Since its launch in 1988, the burden of polio
cases has come down from an estimated 350,000 cases in 125 endemic
countries to 73 cases in two endemic countries, a reduction of more than
99% [1,2]. In 2015, a total of 73 cases caused by wild poliovirus (wPV)
were reported from these two countries: Pakistan (n=54; 74%) and
Afghanistan (n=19; 26%) [3,4]. Compared to year 2014, these
figures reflect 82% reduction of cases in Pakistan (n=306) and
32% for Afghanistan (n=28). Nigeria that reported 6 wPV cases in
2014 did not report any fresh cases in 2015 and was removed from the
list of polio endemic countries in September 2015 [3,4].
The world has witnessed this tremendous progress
using trivalent oral polio vaccine (tOPV) [1]. The use of tOPV has
successfully eliminated wild poliovirus type 2 (wPV2), and wild
poliovirus type 3 (wPV3), which have not been detected globally since
1999 and November 2012, respectively [1]. Four of the six World Health
Organization (WHO) regions have been certified as polio free: the
Americas in 1994, the Western Pacific Region in 2000, the European
Region in 2002, and the South East Asia Region in March 2014 [2,3]. The
four main strategies used to achieve polio elimination are as follows
[1].: (a) Using tOPV in routine immunization; (b)
Strengthened polio disease surveillance; (c) Supplemental
immunization activities (SIAs); and (d) Mop-up campaigns in areas
with sustained transmission.
Polio Situation in Pakistan
The regions of persistent polio transmission in
Pakistan are geographically grouped into four areas [5]. In the north of
Pakistan, a few districts of Khyber Pakhtunkhwa (KP), agencies of The
Federally Administered Tribal Areas (FATA) are examples of reservoir
areas of wPV transmission [5]. Towards south, the other two reservoir
areas are located in the provinces of Sindh and Baluchistan. Although
the greatest challenge remains in specific small areas, eradication
still seems an uphill task [5].
Main reasons behind the huge upsurge in 2014 are
claimed to be militancy and ‘refusal families’ in FATA and KP. However,
larger threats to polio campaign in Pakistaninclude program
mismanagement, campaign design, poor data quality from the field leading
to miscalculation in vaccination coverage estimates, and estimated poor
quality of vaccine administered across the country [6].
Pakistan health agencies, other international
agencies, and local civil society organizations have taken several steps
to strengthen its OPV program. Pakistan has introduced injectable polio
vaccine (IPV) in its routine Expanded Program on Immunization (EPI)
starting from 20th August 2015 [5]. IPV will benefit more than four
million children in Pakistan every year. Frequent movement of Afghan
refugees in the bordering areas of FATA and KP already serving as polio
reservoirs further complicates the situation [5]. Pakistan and
Afghanistan have realized that they need to coordinate intensely in
polio eradication drives.
Pakistan has never reported a polio case count as low
as in 2015 and till date in 2016. The country is still aiming at a shift
from the trivalent to bivalent OPV, but will not be able to completely
withdraw OPV even for years after the target date, thus causing a delay
in containment and certification [5, 6]. It is hoped that coordinated
activities with partner support will help achieve polio-free status in
the near future.
Afghanistan: The Current Scenario
Challenges to interrupting poliovirus transmission in
Afghanistan include: limited healthcare infrastructure and personnel,
low routine vaccination coverage, high rates of poverty and illiteracy,
cultural norms that may restrict caregiver interaction with vaccinators,
and subpopulations that travel frequently to border areas of Pakistan,
where wPV transmission is endemic [7]. Supplementary immunization
activities (SIAs) are hampered by areas of armed conflicts, limited
monitoring and evaluation of coverage, and insufficient local program
accountability, and effectiveness to reach all children [7].
The frequent cross-border migration of ethnic groups
shared with Pakistan requires close coordination of each country’s
respective immunization efforts [7,8]. At the beginning of 2016,
Pakistan and Afghanistan decided to increase micro-synchronization of
polio campaigns at the border, closer monitoring of nomadic movement
across borders, strengthening of transit vaccination, and holding of
synchronized polio campaigns in future [5].
The success story of Polio Eradication in India and
Nigeria
A. India
The critical lessons learnt from India’s elimination
of WPV are as follows [8]:
a) India engaged every level of government
and made district administrators lead task forces to review SIA
planning and implementation;
b) Developed strong communication strategies;
c) Optimized vaccination team composition by
including one male and one female member from local community to
facilitate entry into households;
d) Developed and validated microplans in
which, all houses in the area were numbered and realistic workloads
established for each vaccination team;
e) Real time monitoring of campaign quality
and independent coverage assessment at the end of each round;
f) Ensured accountability;
g) Engaged the private sector to increase
program visibility and reach maximal impact.
Several innovative strategies, and tactics to
identify and vaccinate children who were previously being missed were
included [9]:
1. Engaging community and religious leaders in
planning and implementing SIAs in areas with reluctant participants;
2. Finger marking of vaccinated children to help
identify those not yet vaccinated and marking the dwellings of
households visited by vaccination teams to increase the likelihood
of follow-up;
3. Identifying and tracking newborns; targeting
high-risk areas with multiple health interventions and additional
resources;
4. Implementing a strategy for reaching children
at public gatherings and in mobile and transitory populations.
India also conducted research to help overcome
technical and operational barriers including introduction of more
efficacious vaccines (i.e., monovalent OPV in 2005 and bivalent OPV in
2010); seroprevalence and immunogenicity studies and operational studies
such as social network analysis to provide evidence for decision-making
[9].
B. Nigeria
In 2011-12, Nigeria experienced an upsurge of polio
transmission and the country became a net exporter of poliovirus to
polio-free countries [8,10]. However, at the end of 2013, the number of
cases of wPV type 1 infection had decreased by 58%, with no wPV type 3
transmission [10]. wPV transmission in Nigeria was driven by reservoirs
in northern Nigeria [10]. Additionally, three states in the northeast
region suffered from increased militancy and security problems and
several health-care workers doing polio work were killed [8,10].
Nigeria along with the international partners
undertook several programmatic interventions like those described for
India [10]. These interventions were enabled by a focused effort to
obtain the necessary resources, use them effectively and transparently,
provide the needed public health workforce, and ensure accountability
for results [8,10]. This resulted in Nigeria being removed from polio
endemic list in September 2015 [3,4].
Recent Importations of Wild Poliovirus
During 2014, a total of 19/359 (5%) wPV cases were
due to outbreaks following importation into previously polio-free
countries in Central Africa (Equatorial Guinea and Cameroon), the Horn
of Africa (Somalia and Ethiopia), and the Middle East (Iraq and Syria)
[4]. Among these countries, Guinea and Iraq reported imported cases of
wPV after remaining polio free for more than a decade [4]. Israel in
2013 detected wPV in environmental samples in two of its cities, which
were genetically traced to Pakistan, however a massive public health
campaign prevented occurrence of clinical cases [11]. Thus, as long as
wPV circulates anywhere in the world, all countries are at a risk of
reintroduction and also at risk for epidemics arising from such imported
WPV.
Risks of Continued Use of OPV
Polioviruses contained in OPV (Sabin viruses) are
live attenuated, which on rare occasions can revert to neurovirulence
and cause vaccine-associated paralytic poliomyelitis (VAPP), clinically
indistinguishable from paralytic poliomyelitis caused by wPVs [12-14].
It is estimated that each year between 250 and 500 cases of VAPP occur
worldwide [1]. The number of VAPP cases far exceeded the number of wPV
cases since 2012, which was ethically unacceptable and thus, led to
change in strategy of polio end game.
In addition to causing VAPP, Sabin viruses may mutate
and subsequently gain the ability to circulate in communities for long
periods of time; these are referred to as vaccine-derived polioviruses
(VDPVs) [1]. VDPVs would have also lost their attenuating mutations and
therefore re-acquired both the neurovirulence and transmission
characteristics of wPVs [1]. On very rare occasions, VDPVs could
potentially re-establish endemic and epidemic transmission, leading to
polio outbreaks from these circulating vaccine derived polioviruses (cVDPVs),
and they are therefore incompatible with polio eradication [1].
Over the past decade, more than 40% of VAPP and 90%
of the cVDPV cases have been caused due to the type 2 polio component
contained in tOPV [15]. In 2015, 29 cases of cVDPs were reported
globally with most (n=26) from non-endemic countries and two from
Pakistan [4]. Since wPV2 hasn’t been reported since1999, the risks of
delivering OPV2 outweigh the benefits.
IPV- A Risk Mitigation Strategy
To secure a polio free world from both wPV and cVDPs,
the GPEI’s "Polio Eradication and Endgame Strategic Plan (PEESP)
2013-18" has introduced IPV alongside the OPV [14]. Since the last
natural case caused by poliovirus type 2 occurred in 1999 and the
poliovirus type 2 causes most cases of VAPP and cVDPs as explained
previously, removal of poliovirus type 2, from the current tOPV is the
most logical next step in PEESP 2013-18 [14]. Using a bivalent OPV (bOPV),
containing Sabin poliovirus type 1 and 3 without type 2 virus has
started in April 2016. This will be followed by withdrawal of all OPV in
2019-20 [14]. Since, bOPV has higher immunogenicity per dose [16],
seroconversion rates against type 1 and type 3 will improve and further
generation of type 2 cVDP will stop [17]. However, bOPV use alone is
associated with some risk of type 2 outbreaks in low coverage
populations with low immunity against type 2 viruses [17]. The source
for such outbreaks can be tOPV if the world is using both trivalent and
bivalent OPV at the same time, leading to new type 2 cVDPs [17].
Persistant cVDPs defined as cVDPs circulating for more than 6 months can
occur in normal or in immunocompromised patients (iVDPs) [1, 14].
Outbreaks due to breach in laboratory containment of type 2 virus can be
another source, as happened in India in 2002 and 2003 [18]. In view of
the above-mentioned risks due to switch to bivalent vaccine the PEESP
2013-18 recommends global introduction of at least one dose of IPV into
every country’s routine immunization schedule [14]. All 156 countries
using tOPV are supposed to introduce IPV prior to the switch from 17
1. Sutter RW, Kew OM, Cochi SL, Aylward B. Poliovirus
vaccine—live. In: Plotkin SA OW, Offit PA, ed. Vaccines.
Sixth ed. Edinburgh, United Kingdom: Elsevier; 2013:598-645.
2. WHO 2014. Cases of Wild Poliovirus by Country and
Year. Available from: http://polioeradication.org/Portals/0/Document/Data&Monitoring/Wild_poliovirus_
list_2009_2014_23DEC.pdf. Accessed March 4, 2016.
3. Global Polio Eradication Initiative 2016 Data and
Monitoring. Avialable from:
http://www.polioeradication.org/Dataandmonitoring.aspx. Accessed
March 4, 2016.
4. Progress towards polio eradication worldwide,
2014-2015. Wkly Epidemiol Rec.2015;90:253-9.
5. Qazi J. End of year 2015 in polio endemic
Pakistan: Yet another beginning towards end. Food Environ Virol.
2016;8:109-11.
6. Khan T, Qazi J. Hurdles to the global antipolio
campaign in Pakistan: An outline of the current status and future
prospects to achieve a polio free world. J Epidemiol Community Health.
2013;67:696-702.
7. Simpson DM, Sadr-Azodi N, Mashal T, Sabawoon W,
Pardis A, Quddus A, et al. Polio eradication initiative in
Afghanistan, 1997-2013. J Infec Dis. 2014;210:S162-72.
8. Bahl S, Kumar R, Menabde N, Thapa A, McFarland J,
Swezy V, et al. Polio-free certification and lessons
learned—South-East Asia region, March 2014. MMWR Morb Mortal Wkly Rep.
2014;63:941-6.
9. Nasir UN, Bandhyopadhyay AS, Montagnani F, Akite
JE, Mungu EB, Uche IV, et al. Polio elimination in Nigeria: A
review. Hum Vaccin Immunother. 2016;12:658-63.
10. Vaz RG, Mkanda P, Nsubuga P, Ado M, Etsano A.
Public health innovations on the way to interruption of poliovirus
transmission in Nigeria. J Infec Dis. 2016;Suppl 3:S65-6.
11. Kaliner E, Kopel E, Anis E, Mendelson E, Moran-Gilad
J, Shulman LM, et al. The Israeli public health response to wild
poliovirus importation. Lancet Infect Dis. 2015;15:1236-42.
12. de Oliveira LH, Struchiner CJ. Vaccine-associated
paralytic poliomyelitis: a retrospective cohort study of acute flaccid
paralyses in Brazil. Int J Epidemiol. 2000;29:757-63.
13. John TJ. Vaccine-associated paralytic polio in
India. Bull World Health Organ. 2002;80:917.
14. Sutter RW, Platt L, Mach O, Jafari H, Aylward RB.
The new polio eradication end game: rationale and supporting evidence. J
Infec Dis. 2014;210:S434-8.
15. Aylward B, Yamada T. The polio endgame. N Engl J
Med. 2011;364:2273-5.
16. Sutter RW, John TJ, Jain H, Agarkhedkar S,
Ramanan PV, Verma H, et al. Immunogenicity of bivalent types 1
and 3 oral poliovirus vaccine: A randomised, double-blind, controlled
trial. Lancet. 2010;376:1682-8.
17. Orenstein WA, Committee on Infectious D.
Eradicating polio: How the world’s pediatricians can help stop this
crippling illness forever. Pediatrics. 2015;135:196-202.
18. Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection
of MEF-1 laboratory reference strain of poliovirus type 2 in children
with poliomyelitis in India in 2002 & 2003. Indian J Med Res.
2003;118:217-23.
19. WHO 2016 India Expert Advisory
Group (IEAG) February 26th 2016 meeting Avialable from:
http://www.who.int/immunization/sage/meetings/2016/april/3_Conclusions_recommendations_mini_
IEAG_26_Feb2016_NewDelhi.pdf. Accessed May 02, 2016.
20. Polio vaccines: WHO position paper – March, 2016.
Wkly Epidemiol Rec. 2016;91:145-68.
21. Resik S, Tejeda A, Mach O, Fonseca M, Diaz M,
Alemany N, et al. Immune responses after fractional doses of
inactivated poliovirus vaccine using newly developed intradermal jet
injectors: A randomized controlled trial in Cuba. Vaccine.
2015;33:307-13.
22. Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE,
Weldon WC, et al. Early priming with inactivated poliovirus
vaccine (IPV) and intradermal fractional dose IPV administered by a
microneedle device: A randomized controlled trial. Vaccine.
2015;33:6816-22.